Please login to the form below
New US head for Daiichi Sankyo
Glenn Gormley replaces John Gargiulo who steps down as president and CEO
Daiichi Sankyo has announced a shake-up of its senior leadership team in the US.
John Gargiulo well step down as president and CEO of the group's US subsidiary Daiichi Sankyo Inc to be replaced by Dr Glenn Gormley, who takes on the role of president and chairman.
Dr Gormley (pictured right) will also continue in his existing roles as president, Daiichi Sankyo pharma development; global head of R&D; and senior executive officer.
In addition to the announcement that Gargiulo is to step down as president and CEO, he will also leave his role as head of Daiichi's commercial division. He is succeeded there by Greg Barrett, who now holds the title of acting president, Daiichi Sankyo administrative and commercial operations.
The move is a step up for Barrett, who most recently held the position of VP, marketing and managed markets in the US.
No reason was given for the departure of Gargiulo who has been with the company in the US since 1996.
COVID-19 Updates and Daily News
Featured jobs
- Client Services Director, MRNA/ Covid 19, Medical Communications...
-
Highly competitive salary
-
B2B media account director
-
Competitive salary
- Senior Account Exec > CSD – Medical Communications – UK, Lond...
-
Highly Competitive Salary, Bonus &Benefits
- Scientific Director, MRNA/ Covid 19, Medical Communications, UK
-
Six figure salary
- Principal Medical Writer, MRNA/ Covid 19, Medical Communications...
-
Highly competitive salary
- FREELANCE Associate Director - Healthcare PR - Remote or London
-
Superb Day Rate &Benefits
- Medical Writers > Scientific Directors – Medical Communicatio...
-
Highly Competitive Salary, Bonus &Benefits
- Vaccines writer – career opportunity to move into medcomms from ...
-
Highly competitive salary
- AM / Senior Account Manager – Healthcare PR - London / Remote
-
Highly Competitive Salary, Bonus &Benefits
- Omicron rise prompts tougher measures in England
- Pfizer/BioNTech promote booster against Omicron
- What is EVID AI?
- Virtual meeting technologies for reducing emissions and waste in the healthcare industry
- AstraZeneca and Ionis sign $3.6bn deal for eplontersen
- Roche’s Actemra approved for severe COVID-19 in Europe
- Results for Merck’s oral cholesterol inhibitor show it to be ‘highly effective’
- Sanofi to buy acne specialist Origimm
- Gilead’s Trodelvy approved for triple-negative breast cancer in Europe
- Promoting off-label use: where to draw the line?
- Synairgen’s SNG001 advances into phase 3 COVID-19 trial
- Engaging HCPs on their own terms: how pharma can adapt to the post-pandemic digital era
PMHub
JPA Health
JPA Health is an award-winning public relations, marketing and advocacy firm known for sharing our clients’ commitment to making people...
Latest intelligence
- Virtual meeting technologies for reducing emissions and waste in the healthcare industry
- ...
- Diversity in clinical trials: looking back at our 2021 blogs
- In this blog, we look back at the Innovative Trials' Equality & Diversity (E&D) committee blogs across 2021...
- What does the future hold for Light-chain Amyloidosis?
- Recent advances in the understanding and treatment are reforming pharma’s approach to the management of this rare disease. With a new standard of care rapidly developing, what does the landscape...
